Biohaven Pharmaceutical
Biohaven is engaged in the identification and development of clinical stage neuroscience compounds targeting the glutamatergic system.
Launch date
Employees
Market cap
AUD5.6b
Enterprise valuation
AUD4.9b (Public information from Sep 2024)
Share price
$39.4 BHVN
New Haven Connecticut (HQ)
Financials
Estimates*
| USD | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenues | - | - | - | - | - | 10.0m | 16.0m |
| % growth | - | - | - | - | - | - | 60 % |
| EBITDA | - | (114m) | (218m) | (567m) | (429m) | - | - |
| Profit | - | (119m) | (214m) | (570m) | (408m) | - | - |
| EV / EBITDA | - | -48.7x | -45.5x | - | - | - | - |
| R&D budget | - | 98.5m | 181m | 437m | 373m | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
N/A | Spinout | ||
* | N/A | N/A | IPO |
* | $450m | Post IPO Equity | |
* | $11.6b Valuation: $11.6b -53.3x EV/LTM EBITDA | Acquisition | |
* | N/A | $225m | Post IPO Equity |
* | N/A | $230m | Post IPO Equity |
| Total Funding | - | ||
